4th International Conference on Rare Diseases and Orphan Drugs

Coalesce Research Group is pleased to announce the 4th International Conference on Rare Diseases and Orphan Drugs, taking place on October 22–23, 2026, in Barcelona, Spain.

This 2-day conference provides a global platform for experts, stakeholders, and advocates to explore advancements, challenges, and opportunities in the rare diseases and orphan drugs sector.

The primary goal is to raise awareness, foster collaboration, and accelerate progress in addressing the complex needs of individuals affected by rare diseases. The event encourages dialogue and knowledge exchange across research, drug development, patient care, advocacy, and policy-making.

Topics may include

• Disease epidemiology and genetics
• Advances in diagnosis and screening
• Therapeutic interventions and treatment approaches
• Drug discovery and development strategies
• Regulatory pathways and orphan drug designation
• Patient-centered care and access to treatments
• Health economics and reimbursement issues
• Patient advocacy, support, and empowerment

The program features keynote presentations, plenary sessions, panel discussions, poster presentations, workshops, and networking opportunities. Exhibits may showcase the latest advancements in rare disease research, diagnostics, and therapeutics.

Rare Diseases 2026 plays a vital role in advancing research, innovation, and collaboration to improve outcomes and quality of life for individuals living with rare diseases.

Who can attend?

• Medical Professionals: Doctors, Specialists, Nurses, and Pharmacists
• Researchers and Scientists
• Pharmaceutical Industry Representatives
• Patient Advocates and Organizations
• Regulatory Authorities
• Healthcare Administrators
• Academics and Educators
• Investors and Venture Capitalists
• Government Representatives: Policymakers, Lawmakers, and Officials
• Industry Stakeholders

Register

The Royal Australasian College of Physicians publishes notices of events as a service to members. Such publication does not constitute endorsement or mandating of the event.